Edinburgh has 13 active biotech investors deploying in 2026. Epidarex just closed $145M. Here's who's writing checks now.
Scotland's life sciences sector has 750 companies and 46,000 employees. Edinburgh BioQuarter is one of the UK's most concentrated life sciences clusters.
UK biotech VC hit £516M in Q1 2026 - up 17% on Q4 2025. Edinburgh captures a meaningful share through its hospital, research institute, and University of Edinburgh spinout pipeline.
Epidarex Capital closed Fund IV at $145M in January 2026. Bioliberty raised £7.7M Series A in March 2026. BIOCAPTIVA raised £1.6M in a seed led by Archangels in 2026. Edinburgh biotech is actively funded right now.
Set up an Ellty data room with your IP, clinical data, and cap table before outreach. Edinburgh biotech investors ask for these documents before any first meeting.
| Stage | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Epidarex Capital | Seed to Series A | $1M-$15M | Therapeutics, medtech, life sciences | epidarex.com |
| Archangels | Seed to Series B | £500K-£5M | Life sciences, tech, IP-rich | archangelsonline.com |
| Eos Advisory | Seed to Series A | £20K-£500K | Life sciences, healthtech, diagnostics | eos-advisory.com |
| Old College Capital | Pre-seed to Series A | £100K-£300K | Biotech, AI, university spinouts | edinburgh-innovations.ed.ac.uk |
| Scottish National Investment Bank | Seed to growth | £1M-£50M | Life sciences, tech, Scottish impact | thebank.scot |
| Scottish Enterprise | Seed to Series A | Match to lead investor | Scottish biotech, life sciences | scottish-enterprise.com |
| Maven Capital Partners | Seed to growth | £1M-£5M | Life sciences, tech, Scottish | mavencp.com |
| British Business Bank | Seed to Series A | Via Epidarex Fund IV | Life sciences, biotech | british-business-bank.co.uk |
| Parkwalk Advisors | Seed to Series A | £500K-£5M | University spinouts, biotech, medtech | parkwalk.vc |
| Deepbridge Capital | Seed to Series A | £250K-£3M | Life sciences, biotech, EIS | deepbridgecapital.com |
| Techstart Ventures | Pre-seed to seed | Up to £750K | Biotech, life sciences, tech | techstart.vc |
| Foresight Group | Seed to growth | £1M-£5M | Life sciences, regional growth | foresight.group |
| Hanna Capital | Seed to Series A | Undisclosed | Healthtech, life sciences | hannacapital.com |
See which biotech VCs open your deck
Build an Ellty data room. Track which investors review your clinical and IP docs.
Start free 14-day trialWhat is an Edinburgh biotech investor?
An Edinburgh biotech investor backs therapeutics, diagnostics, medtech, and life sciences companies. They're different from generalist VCs - they evaluate clinical data, IP ownership, and regulatory pathways that most software investors don't understand.
Edinburgh's biotech investors have direct pipelines from the University of Edinburgh and Edinburgh BioQuarter. The cluster combines NHS hospitals, research institutes, and a concentrated group of specialist investors.
Most Edinburgh biotech investors write £100K to £5M at seed and Series A. Epidarex and SNIB write larger checks at later stages. Check sizes scale with clinical stage and IP strength.
Compare Edinburgh AI investors if your biotech product has a strong AI or ML component. Several AI-focused funds back Edinburgh biotech companies with computational biology or AI-driven drug discovery angles.
The next three years represent a highly attractive window for investing in a new wave of biotech innovation. We're deploying our largest fund to build the next generation of life science companies from breakthrough UK and US science.
13 Edinburgh biotech investors
1. Epidarex Capital
Epidarex Capital is Edinburgh's flagship biotech VC. They closed Fund IV at $145M in January 2026 - backed by British Business Bank (£50M cornerstone), Scottish National Investment Bank (£15M), and Strathclyde Pension Fund. They invest in therapeutics, medtech, and diagnostics at seed and Series A in the UK and US. Their portfolio includes Apellis Pharmaceuticals (FDA-approved), Enterprise Therapeutics, and Nodthera.
- Recent Deals: Fund IV first close $145M (January 2026); Edinburgh Molecular Imaging lead investment; Apellis FDA approval exit; oncology and cardiometabolic focus
- LinkedIn: Epidarex Capital LinkedIn
- Sector Focus: Therapeutics, medtech, diagnostics, oncology
- Stage Focus: Seed to Series A
- Location: Edinburgh, UK and US
- Website: epidarex.com
2. Archangels
Archangels is the world's oldest continuously operating angel syndicate, founded in Edinburgh in 1992. They led BIOCAPTIVA's £1.6M seed in 2026 - a University of Edinburgh biotech spinout. They also backed Cytomos' oversubscribed funding round in 2024 and Bioliberty's Series A in 2026. Members write £10K-£100K individually and pool to £500K-£5M per deal. They only back Scottish companies.
Use Ellty to share your IP assignment documents and clinical data with Archangels members. Their syndicate model means multiple angels review independently before group decisions.
- Recent Deals: BIOCAPTIVA £1.6M seed lead (2026); Bioliberty Series A (2026); Cytomos funding round; £41M co-investment leveraged in 2025
- LinkedIn: Archangels LinkedIn
- Sector Focus: Life sciences, tech, IP-rich companies
- Stage Focus: Seed to Series B
- Location: Edinburgh, UK (Scotland only)
- Website: archangelsonline.com
3. Eos Advisory
Eos Advisory is a St Andrews-based science and tech investor that has backed 26 Edinburgh and Scottish life sciences companies. They write £20K to £500K at seed and Series A. Their portfolio reached £121M valuation in 2025. They led the seed round for Concinnity (Edinburgh biotech developing AI-driven RNA control systems) alongside Old College Capital and Scottish Enterprise.
- Recent Deals: Concinnity £3M seed co-investor; Scarlet Therapeutics (most recent 2026 investment); Nami Surgical follow-on (2026); Dxcover portfolio; 3 investments in 2025, 4 in 2026
- LinkedIn: Eos Advisory LinkedIn
- Sector Focus: Life sciences, healthtech, diagnostics, cleantech
- Stage Focus: Seed to Series A
- Location: St Andrews, Scotland
- Website: eos-advisory.com
4. Old College Capital
Old College Capital is the University of Edinburgh's in-house VC fund. They write £100K to £300K into pre-seed and seed biotech, AI, and deeptech companies with University of Edinburgh connections. They backed BIOCAPTIVA's £1.6M seed in 2026, Concinnity's £3M seed, and Bioliberty's Series A in 2026. Approach Old College Capital before any external investor if you're a University spinout.
Set up an Ellty data room with your technology transfer agreement, IP filing status, and clinical rationale. Old College Capital checks spinout IP ownership on day one.
- Recent Deals: BIOCAPTIVA seed (2026); Concinnity £3M seed; Bioliberty Series A (March 2026); Neuranics seed (April 2025); 40+ portfolio companies
- LinkedIn: Old College Capital LinkedIn
- Sector Focus: Biotech, AI, life sciences, university spinouts
- Stage Focus: Pre-seed to Series A
- Location: Edinburgh, UK
- Website: edinburgh-innovations.ed.ac.uk
5. Scottish National Investment Bank
The Scottish National Investment Bank (SNIB) is Scotland's state development bank. They led Bioliberty's £3M tranche of a £6.2M Series A in March 2026 and committed £15M to Epidarex Fund IV. They write £1M to £50M and invest in biotech companies with clear Scottish economic impact. Later-stage Edinburgh biotech founders with NHS Scotland partnerships should approach SNIB directly.
- Recent Deals: Bioliberty £3M Series A lead (March 2026); Epidarex Fund IV £15M commitment (January 2026); £784.8M committed portfolio; life sciences mandate
- LinkedIn: SNIB LinkedIn
- Sector Focus: Life sciences, tech, Scottish economic impact
- Stage Focus: Seed to growth
- Location: Edinburgh, UK
- Website: thebank.scot
Send trackable links to Edinburgh biotech VCs
Use Ellty to see which investors open your clinical data and IP documents.
Start free 14-day trial6. Scottish Enterprise
Scottish Enterprise runs the Scottish Co-Investment Fund (SCIF), matching private investment pound for pound. They co-invested in BIOCAPTIVA's £1.6M seed in 2026, Concinnity's £3M seed, and Cytomos' funding round. They don't lead but significantly increase round size for Scottish biotech founders who already have a private lead.
- Recent Deals: BIOCAPTIVA seed (2026); Concinnity £3M seed; Cytomos funding round; SCIF match funding mandate; Scottish life sciences focus
- LinkedIn: Scottish Enterprise LinkedIn
- Sector Focus: Scottish biotech, life sciences, innovation
- Stage Focus: Seed to Series A
- Location: Edinburgh, UK
- Website: scottish-enterprise.com
7. Maven Capital Partners
Maven Capital Partners participated in Concinnity's £3M seed round in 2026 alongside Eos Advisory and Old College Capital. They write £1M to £5M into life sciences and tech companies and run Northern Powerhouse and Scottish regional funds. Edinburgh biotech founders with recurring revenue or near-clinical-stage assets suit Maven's mandate.
Read how to prepare for due diligence before approaching Maven. They expect a complete regulatory pathway and CMC documentation before any IC meeting.
- Recent Deals: Concinnity £3M seed (2026); life sciences and tech mandate; Northern Powerhouse and Scottish regional funds; seed to growth
- LinkedIn: Maven Capital Partners LinkedIn
- Sector Focus: Life sciences, tech, Scottish
- Stage Focus: Seed to growth
- Location: Edinburgh and UK regions
- Website: mavencp.com
8. British Business Bank
The British Business Bank committed a £50M cornerstone investment to Epidarex Capital Fund IV in January 2026 - their largest-ever single biotech commitment. They deploy through partner funds including Epidarex, Parkwalk, and Deepbridge rather than directly. Edinburgh biotech founders access BBB capital via fund managers registered as BBB delivery partners.
- Recent Deals: Epidarex Fund IV £50M cornerstone (January 2026); BBB delivery partner funds active; life sciences mandate; seed to Series A via funds
- LinkedIn: British Business Bank LinkedIn
- Sector Focus: Life sciences, biotech, via fund managers
- Stage Focus: Seed to Series A via partner funds
- Location: UK-wide via partner funds
- Website: british-business-bank.co.uk
9. Parkwalk Advisors
Parkwalk Advisors is one of the UK's most active university spinout investors. They launched the Northern Universities Venture Fund (NUVF) in June 2025 with Northern Gritstone, covering University of Edinburgh spinouts. They write £500K to £5M using EIS structures. Edinburgh biotech spinouts with University of Edinburgh IP should approach Parkwalk early.
Use Ellty to organise your IP licensing, technology transfer agreements, and patent filings. Parkwalk expects these on day one before committing to a term sheet.
- Recent Deals: NUVF EIS fund launched June 2025; University of Edinburgh biotech spinout mandate; Cytotrait £3M seed participation (March 2026); EIS structures
- LinkedIn: Parkwalk Advisors LinkedIn
- Sector Focus: University spinouts, biotech, medtech
- Stage Focus: Seed to Series A
- Location: London with Scottish university deal flow
- Website: parkwalk.vc
10. Deepbridge Capital
Deepbridge Capital backs life sciences and tech founders using SEIS/EIS structures. They write £250K to £3M and suit Edinburgh biotech founders raising first institutional rounds with defensible IP and a credible regulatory pathway. Their mandate covers therapeutics, diagnostics, and biomedical devices.
- Recent Deals: Active life sciences EIS mandate; £250K-£3M checks; therapeutics and diagnostics focus; SEIS/EIS structures; seed to Series A
- LinkedIn: Deepbridge Capital LinkedIn
- Sector Focus: Life sciences, biotech, EIS
- Stage Focus: Seed to Series A
- Location: North West UK with UK-wide life sciences mandate
- Website: deepbridgecapital.com
11. Techstart Ventures
Techstart Ventures is a government-backed pre-seed investor in Scotland and Northern Ireland. They write first checks up to £750K and back biotech, SaaS, and tech founders at inception. They are backed by the Scottish Government Scottish Growth Scheme and co-invest in Scottish biotech companies at pre-seed alongside angels and university funds.
- Recent Deals: Active Scottish Growth Scheme mandate; biotech and life sciences mandate; up to £750K first checks; 118+ portfolio companies; Scotland-based requirement
- LinkedIn: Techstart Ventures LinkedIn
- Sector Focus: Biotech, life sciences, tech
- Stage Focus: Pre-seed to seed
- Location: Edinburgh, UK
- Website: techstart.vc
12. Foresight Group
Foresight Group backed uFraction8 in a £3.4M round led by Foresight in 2025 - a Scottish life sciences company developing bioprocessing technology. They write £1M to £5M and run regional funds targeting Scottish and Northern life sciences companies. Edinburgh biotech founders at seed with commercial traction should include Foresight in their pipeline.
Read what documents go in a data room before approaching Foresight. They run thorough technical due diligence on bioprocessing and manufacturing claims.
- Recent Deals: uFraction8 £3.4M lead (2025); active life sciences regional mandate; Scotland and Northern UK deal flow; seed to growth
- LinkedIn: Foresight Group LinkedIn
- Sector Focus: Life sciences, biotech, regional growth
- Stage Focus: Seed to growth
- Location: UK-wide, Scotland in mandate
- Website: foresight.group
13. Hanna Capital
Hanna Capital participated in Bioliberty's £7.7M Series A in March 2026 as an existing investor, alongside SNIB, Archangels, Eos Advisory, and Old College Capital. They back healthtech and life sciences companies in the UK and internationally. Edinburgh healthtech founders with a robotics, digital health, or rehabilitation angle should research Hanna Capital alongside specialist life sciences funds.
- Recent Deals: Bioliberty £7.7M Series A (March 2026); Bioliberty pre-Series A participation (2025); healthtech and life sciences mandate
- LinkedIn: Hanna Capital LinkedIn
- Sector Focus: Healthtech, life sciences
- Stage Focus: Seed to Series A
- Location: International with UK portfolio
- Website: hannacapital.com
How Edinburgh biotech fundraising works
Edinburgh biotech rounds almost always involve a lead investor alongside Scottish Enterprise co-investment. SCIF matches the private lead pound for pound. Most rounds at seed also include Old College Capital or Archangels as secondary investors.
Clinical-stage companies at Series A attract larger institutional investors like Epidarex and SNIB. Pre-clinical and seed-stage companies rely more on Eos Advisory, Archangels, and Techstart alongside SCIF.
Read virtual data room for biotech to structure your IP, clinical, and regulatory documents. Use Ellty to send materials with trackable links so you know which investors engage before follow-up.
What to research before reaching out
Check each fund's portfolio for companies at a similar clinical stage to yours. A fund that has never backed a pre-clinical company won't make an exception for you.
Verify the fund is still deploying. Epidarex Fund IV just closed in January 2026 - they're actively writing checks. A fund with no new investments since 2023 is in harvest mode.
Check LinkedIn activity of the partners. Active investors post about deals and sector trends. Partners who haven't engaged publicly in 12+ months may have moved on from active investing.
How to approach Edinburgh biotech investors
Start with the University of Edinburgh's Edinburgh Innovations team if you're a spinout. They have direct relationships with Old College Capital, Parkwalk, and Epidarex. A warm intro from Edinburgh Innovations closes faster than any cold email.
For Archangels and Eos Advisory, attend LINC Scotland and Life Sciences Scotland events. Both organisations host regular investor-founder networking. Personal introduction via event contacts converts significantly better than cold outreach.
Don't pitch Epidarex without a clinical data package. Their $145M fund backs companies with breakthrough science. Show preclinical results, IP ownership, and regulatory pathway before requesting a first meeting.
How to pitch an Edinburgh biotech investor
Four steps that match how Scottish life sciences VCs evaluate founders before writing a check.
- 1.Confirm IP ownership and university transfer statusEdinburgh biotech VCs check IP ownership on the first call. Prepare early.
- 2.Show your clinical or preclinical data packageEpidarex and Archangels won't engage without a credible scientific rationale.
- 3.Map your regulatory pathway before outreachUK MHRA or CE mark route must be clear at seed. Clarify this upfront.
- 4.Identify a SCIF-eligible co-lead before applyingScottish Enterprise match funding needs a private lead to trigger it.
How Ellty helps you land an Edinburgh biotech investor
Prepare your clinical data and IP documents before the first meeting. Investors ask for both immediately.
- 1.Build a biotech data room with IP and clinical docsUpload IP filings, preclinical data, and cap table. One secure link.
- 2.Control access to sensitive clinical and IP documentsRequire email before viewing. Restrict downloads on clinical trial data.
- 3.See which investors review your clinical data pagesTrack who opens your IP section. Follow up with those who engage.
Common questions from Edinburgh biotech founders
- Archangels and Old College Capital require Scottish operations. Epidarex and Foresight invest UK-wide.
- Eos and Techstart back pre-clinical. Epidarex and SNIB prefer clinical-stage with proof of concept.
- Archangels is an angel syndicate writing smaller checks. Epidarex is a specialist VC writing $1M-$15M.
- Before first contact. Biotech VCs ask for IP and clinical docs before any first meeting.
- You need a named private lead first. Then apply to Scottish Enterprise with your lead investor confirmed.
- Yes. SNIB specifically backs companies with Scottish economic impact including NHS Scotland relationships.
